Midazolam Kalceks (Midazolam)

Midazolam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor, increasing chloride ion flow into neurons. This amplifies inhibitory signals in the brain, producing sedation, anxiolysis, anticonvulsant effects, and muscle relaxation.

The specific dose of Midazolam Kalceks is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, route of administration, and desired depth of sedation. No fixed dosing regimen is provided here.

Safety data for Midazolam during pregnancy and lactation are limited. Because it crosses the placenta and may be excreted in breast milk, it is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Midazolam is a short‑acting benzodiazepine, offering faster onset and shorter recovery than longer‑acting agents such as diazepam. Compared with other sedatives like propofol, Midazolam provides greater amnestic properties but may have a slower emergence profile, making choice dependent on the clinical situation.

Midazolam Kalceks should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain potency and sterility.

Midazolam can be given by intramuscular, intravenous, or rectal routes, depending on the clinical indication and setting. The route is selected by the treating clinician, who also determines the appropriate concentration and infusion rate if administered intravenously.

The most critical risks include severe respiratory depression, profound hypotension, and paradoxical reactions such as agitation or aggression. Continuous monitoring of breathing, oxygen saturation, and cardiovascular status is essential during and after administration.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in individuals who have taken large amounts of other central nervous system depressants. Caution is also advised for patients with myasthenia gravis or severe hepatic impairment.